Cost-effectiveness analysis of retlirafusp alfa combined with chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
Background The phase III RELIGHT trial demonstrated that retlirafusp alfa plus CAPOX (RTL-CHE) significantly improved overall survival versus placebo plus CAPOX (PLA-CHE) as first-line treatment for patients with programmed death-ligand 1 (PD-L1)-positive (combined positive score [CPS] ≥ 1), human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. However, the cost-effectiveness of RTL-CHE remains unclear. This study assessed its cost-effectiveness as first-line therapy versus PLA-CHE from the perspective of the Chinese healthcare system. Methods Using data from the RELIGHT trial, a Markov model was developed with a 21-day cycle and a 10-year time horizon. Analyses were conducted from the Chinese healthcare system perspective, with costs and outcomes discounted at 4.5% annually. Outcomes included total costs and quality-adjusted life-years (QALYs). Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER), with a willingness-to-pay (WTP) threshold of $27,906/QALY. One-way and probabilistic sensitivity analyses were performed. Subgroup, scenario, and threshold analyses were also conducted. Subgroup analyses were performed in patients with CPS ≥ 5 and those with CPS ≥ 1 and < 5. Scenario analyses included the intention-to-treat (ITT) population, shorter time horizons, and vial wastage assumptions. Threshold analyses were used to explore price adjustments and determine the cost-effective threshold price. Results In the base-case analysis, RTL-CHE yielded 1.45 QALYs at a total cost of $75,079.76, compared with 0.82 QALYs at a total cost of $11,552.25 for PLA-CHE, resulting in an ICER of $100,837.32 per QALY gained. One-way sensitivity analysis identified retlirafusp alfa cost, body weight, and PFS utility as the most influential parameters. In subgroup analyses, the ICER was $94,856.54 per QALY in patients with CPS ≥ 5 and $126,414.40 per QALY in those with CPS ≥ 1 and < 5. In the scenario analysis of the ITT population, the ICER was $132,323.07 per QALY. The ICERs in the base-case, subgroup, and scenario analyses all exceeded the WTP threshold of $27,906 per QALY. To reach the WTP threshold, the price of retlirafusp alfa would need to fall to $47.41 per 100 mg. Conclusion From the perspective of the Chinese healthcare system, RTL-CHE is not cost-effective as first-line treatment for PD-L1-positive (CPS ≥ 1), HER2-negative advanced G/GEJ adenocarcinoma compared with PLA-CHE.
Authors
- Danxue Huang (ORCID: https://orcid.org/0009-0000-3855-922X)
- Su Li (ORCID: https://orcid.org/0009-0006-5772-2743)
- Jing Xiang (ORCID: https://orcid.org/0000-0003-2026-7354)
- Na Li (ORCID: https://orcid.org/0009-0005-1648-9095)
Institutions
- Liaoning Cancer Hospital & Institute (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fphar.2026.2033820
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00